169269-83-4

Upstream product

• 111-29-5 1 ,5-pentanediol 
• 100-39-0 benzyl bromide 
• 629-30-1 1,7-heptandiol 
• 4541-15-5 5-(benzyloxy)-1-pentanol 
• 124267-23-8 7-(benzyloxy)heptanoic acid 
• 871732-89-7 7-benzyloxy-heptanoic acid methyl ester 
• 871732-99-9 7-benzyloxy-hept-2-enoic acid ethyl ester 
• 78999-24-3 5-benzyloxy-1-pentanal 

Downstream Products

• 871732-90-0 (4R)-3-(7-benzyloxy-1-oxoheptyl)-4-benzyl-2-oxazolidinone 
• 169269-97-0 (R)-3-((S)-1-Methylcarbamoyl-2-phenyl-ethylcarbamoyl)-8-phenoxy-octanoic acid tert-butyl ester 
• 169269-90-3 (R)-8-Benzyloxy-3-((S)-1-methylcarbamoyl-2-phenyl-ethylcarbamoyl)-octanoic acid tert-butyl ester 
• 169269-92-5 (R)-8-Benzyloxy-3-((S)-1-methylcarbamoyl-2-phenyl-ethylcarbamoyl)-octanoic acid 
• 1027325-77-4 (R)-3-((S)-1-Methylcarbamoyl-2-phenyl-ethylcarbamoyl)-8-phenoxy-octanoic acid 
• 169269-93-6 (R)-8-Hydroxy-3-((S)-1-methylcarbamoyl-2-phenyl-ethylcarbamoyl)-octanoic acid tert-butyl ester 
• 169269-88-9 (R)-2-(5-Benzyloxy-pentyl)-succinic acid 4-tert-butyl ester 
• 871733-05-0 (S)-2-[Methyl-((S)-3-methyl-2-{methyl-[(S)-3-methyl-2-(methyl-{(S)-3-methyl-2-[methyl-((S)-2-methyl-oct-7-ynoyl)-amino]-butyryl}-amino)-butyryl]-amino}-butyryl)-amino]-3-phenyl-propionic acid tert-butyl ester 
• 871732-95-5 (S)-2-[Methyl-((S)-3-methyl-2-{methyl-[(S)-3-methyl-2-(methyl-{(S)-3-methyl-2-[methyl-((R)-2-methyl-oct-7-ynoyl)-amino]-butyryl}-amino)-butyryl]-amino}-butyryl)-amino]-3-phenyl-propionic acid tert-butyl ester 
• 871732-91-1 [(2'R),4R]-3-(7-benzyloxy-2-methyl-1-oxoheptyl)-4-benzyl-2-oxazolidinone 
• 871733-01-6 (2R)-7-benzyloxy-2-methyl-heptanoic acid 
• 871732-92-2 (2R)-7-benzyloxy-2-methyl-heptanoic acid methyl ester 

Relevant academic research and scientific papers

The total synthesis and reassignment of stereochemistry of dragonamide

The first total synthesis of dragonamide is reported. The synthesis has led to a reassignment of the configuration at the stereogenic centre on the alkyne-bearing fragment of the molecule.

Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group

In this study, structure-based drug design of matrix metalloproteinase inhibitors [human fibroblast collagenase (HFC), human fibroblast stromelysin (HFS), and human neutrophil collagenase (HNC)] was utilized in the development of potent hydroxamates which